Page 3 - Weight Loss

Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Ozempic, other weight-loss drugs tied to rare, serious eye issue: Study

Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked

Cult Fit co-founder's realistic weight loss lessons for lasting results

From better sleep to mindful hydration, Cult Fit co-founder Rishabh Telang shares six simple, science-backed weight loss tips that fit into real life, no crash diets required

How Ozempic maker Novo Nordisk lost sheen after creating wonder drug

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Ozempic maker's plight shows why managing markets matter for pharma giants

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting market sentiment in high-growth pharma bets

CDMOs gear up for peptide boom amid rising demand for weight-loss drugs

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent expiries such as that of semaglutide in 2026

Ozempic to Mounjaro: India’s in a full-blown weight-loss drug war | Wegovy | Belly-fat | Health drug

India’s weight-loss game is getting serious! The country’s anti-obesity market is now worth ₹628 crore, and it’s climbing fast! Watch this video for a quick look at the top contenders

Think skipping meals is good for your health? Here's what you should know

Skipping meals can increase stress, disrupt hormones, and worsen metabolism. Intermittent fasting offers a smarter, mindful and beneficial approach to eating patterns

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Fact-check | Can Lemon Water Burn Fat? Experts Bust 15 Weight Loss Myths | Health with BS

Does lemon water really burn fat? Or is it just another wellness myth? ???? In this fact-check video, top health and nutrition experts bust 15 of the most common weight loss myths

Can lemon water burn fat? Experts bust 15 weight loss myths you believe

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.

New data shows just how powerful the next weight-loss drugs may be

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

The 1.75 mg and 2.4 mg doses will be priced at ₹24,280, and 2.4 mg will be priced at ₹26,050 for a month

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May